Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study.

Authors

George A. Fisher Jr.

Stanford University, Stanford, CA

George A. Fisher Jr., Rodney F. Pommier , Edward M. Wolin , Pamela L. Kunz , Nilani Liyanage , Susan W. Pitman Lowenthal , Beloo Mirakhur , Montaser F. Shaheen , Aaron Vinik

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 Gastrointestinal Cancers Symposium

bookmark_border

Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study.

First Author: Rodney F. Pommier

insert_chart_outlined

Poster

2018 Gastrointestinal Cancers Symposium

bookmark_border

Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naïve or experienced patients.

First Author: Edward M. Wolin

insert_chart_outlined

Poster

2017 Gastrointestinal Cancers Symposium

bookmark_border

Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.

First Author: Jonathan R. Strosberg

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): Subgroup analysis of the ELECT study.

First Author: Aaron Vinik